Kamada (NASDAQ:KMDA) Announces Earnings Results

Kamada (NASDAQ:KMDA) announced its earnings results on Monday. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.01, FiscalAI reports. The firm had revenue of $52.03 million during the quarter, compared to analyst estimates of $52.51 million. Kamada had a return on equity of 9.38% and a net margin of 12.67%.

Here are the key takeaways from Kamada’s conference call:

• Positive Sentiment: Kamada raised 2026 guidance to $205 million–$208 million in revenue and $52 million–$54 million in adjusted EBITDA. Management also expects another year of double-digit revenue and profitability growth in 2027.
• Positive Sentiment: Nine-month revenue rose 12% to $152.2 million, adjusted EBITDA increased 20% to $40.9 million, and net income grew 29% to $21.4 million. Operating cash flow more than doubled year over year to $37.6 million.
• Positive Sentiment: Demand for KEDRAB remains strong in the U.S. and international markets; management said Kedrion is ordering above its minimum commitment and Kamada has capacity to support further growth. The company expects the demand trend to continue beyond 2026.
• Positive Sentiment: Distribution revenue grew 35% in the first nine months, supported by new biosimilar launches in Israel and expansion into the MENA region. Kamada projects biosimilar revenue of about $10 million in 2028 and $20 million–$25 million by 2030, with at least two more launches planned for 2027.
• Neutral Sentiment: Kamada announced a three-year, approximately $50 million plasma supply agreement, with initial sales expected in the fourth quarter and already included in 2026 guidance. Management noted that benefits from using its own collected plasma in manufacturing have not yet been reflected in results.

Kamada Stock Down 0.1%

Shares of NASDAQ:KMDA traded down $0.01 during midday trading on Wednesday, reaching $8.09. 59,354 shares of the company traded hands, compared to its average volume of 82,793. Kamada has a 12 month low of $6.59 and a 12 month high of $9.35. The firm has a market capitalization of $465.26 million, a price-to-earnings ratio of 18.81, a price-to-earnings-growth ratio of 0.64 and a beta of 0.90. The firm’s fifty day moving average price is $8.06 and its two-hundred day moving average price is $8.00.

Kamada Announces Dividend

The firm also recently disclosed a special dividend, which will be paid on Wednesday, December 9th. Investors of record on Thursday, November 19th will be paid a $0.14 dividend. The ex-dividend date is Thursday, November 19th. Kamada’s payout ratio is currently 34.21%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KMDA. Benchmark restated a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Weiss Ratings cut shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday. Stifel Nicolaus set a $12.00 target price on shares of Kamada in a research report on Monday. UBS Group reissued a “buy” rating and set a $15.00 target price on shares of Kamada in a research report on Friday, September 18th. Finally, Wall Street Zen upgraded shares of Kamada from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, Kamada has a consensus rating of “Buy” and a consensus price target of $13.75.

Kamada Company Profile

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.